Search

  1. ProQR at TIDES to highlight our Axiomer technology

    Blog

    This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer RNA-editing platform technology.

    Two ProQRians standing outside TIDES EU 2022 Conference Entrance

  2. Today marks an expansion of the ProQR and Lilly partnership

    News update

    … focuses on developing potential medicines using our Axiomer RNA editing platform technology. Strategic … drive the advancement of an early-stage technology, like Axiomer, closer to the clinic. Today we are delighted to … announced in September 2021 , applied ProQR’s proprietary Axiomer™ RNA editing platform to target disorders of the …

    Axiomer partnership

  3. “A new way of designing medicines”

    Story

    Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.

    A photo of Bart Klein

  4. ProQR Update August 2022

    Community news

    … ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple … ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple …

    Axiomer RNA editing platform technology

  6. Exploring why companies partner their technology

    Blog

    … focuses on developing potential medicines using our Axiomer™ RNA editing platform technology. Strategic … drive the advancement of an early-stage technology, like Axiomer , closer to the clinic. In any global licensing and …

    Lenka